StockNews.com Begins Coverage on Catalent (NYSE:CTLT)

Investment analysts at StockNews.com initiated coverage on shares of Catalent (NYSE:CTLT) in a research report issued on Thursday. The brokerage set a “sell” rating on the stock.

Several other equities research analysts also recently commented on CTLT. UBS Group reissued a “neutral” rating and set a $63.50 target price (up from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. Barclays upped their price objective on shares of Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a research report on Thursday, January 25th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a research report on Tuesday, February 20th. Finally, Stephens reaffirmed an “equal weight” rating and issued a $63.50 price objective on shares of Catalent in a research report on Thursday, April 4th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $52.46.

Catalent Trading Up 0.0 %

NYSE:CTLT opened at $57.02 on Thursday. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.48 and a quick ratio of 1.73. The firm has a 50-day moving average of $56.87 and a 200-day moving average of $47.74. The company has a market cap of $10.31 billion, a PE ratio of -8.39, a PEG ratio of 6.11 and a beta of 1.20. Catalent has a one year low of $31.45 and a one year high of $67.54.

Catalent (NYSE:CTLT) last posted its earnings results on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.22). The business had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.01 billion. Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The company’s revenue was down 10.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.62 earnings per share. As a group, equities research analysts expect that Catalent will post 0.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of CTLT. Gladius Capital Management LP purchased a new stake in shares of Catalent during the 3rd quarter valued at approximately $28,000. KB Financial Partners LLC purchased a new stake in shares of Catalent during the 1st quarter valued at approximately $30,000. Exchange Traded Concepts LLC purchased a new stake in shares of Catalent during the 3rd quarter valued at approximately $31,000. GAMMA Investing LLC purchased a new stake in shares of Catalent during the 4th quarter valued at approximately $33,000. Finally, Cary Street Partners Investment Advisory LLC lifted its stake in shares of Catalent by 1,162.3% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock valued at $35,000 after buying an additional 709 shares in the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.